Immune to Cancer: The CRI Blog
-
First Immunotherapy Approved for Patients with Small Cell Lung Cancer
Nivolumab (Opdivo®) is now available for patients with metastatic and treatment-resistant small cell lung cancer
-
Living with Small Cell Lung Cancer
Gloria Garcia was diagnosed in 2017 with small cell lung cancer. After combination ipilimumab/nivolumab immunotherapy treatment she…
-
ASCO18 Update: Using Biomarkers to Improve Immunotherapy
The final day of ASCO18 focused on biomarkers’ potential to improve immunotherapy as well as the next-generation…
-
30 Days of CRI Impact
Throughout Cancer Immunotherapy Month in June we’ll be highlighting the 30 most important CRI-funded breakthroughs.
-
AACR18 Recap: Immunotherapy in the Spotlight
Immunotherapy took center stage and dominated the headlines at AACR18.
-
AACR18 Day 3 Update: Lung Cancer in the Spotlight, Immune Memory, and New Immunotherapy Biomarkers
Day 3 of AACR18 highlighted potentially “practice-changing” immunotherapy breakthroughs in lung cancer, and insights into the factors…
-
Durvalumab Becomes First Immunotherapy Approved for Stage III Lung Cancer
Immunotherapy tripled the median progression-free survival rate among lung cancer patients compared to those who received only…
-
Recent FDA Announcements Herald Advances in Personalized Approaches Against Cancer
Two tumor-profiling tests recently authorized by the FDA enable doctors to tailor their treatments more effectively to…
-
FDA approves Keytruda combo for first-line lung cancer treatment
Patients in the U.S. who have advanced nonsquamous non-small cell lung cancer can now receive Keytruda as…